The Technical Analyst
MannKind Corp [MNKD]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
MannKind Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.49% $4.08
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 103.31 mill |
| EPS: | -0.0400 |
| P/E: | -102.00 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 270.42 mill |
| Avg Daily Volume: | 2.98 mill |
| RATING 2024-04-18 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Buy | |
| DE: | Strong Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -102.00 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -17.35x |
| Company: PE -102.00 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.83 - 4.33 ( +/- 6.18%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-27 | Sabella Lauren M | Sell | 17 084 | Common Stock, $.01 Par Value |
| 2024-02-04 | Tross Stuart A | Buy | 15 290 | Common Stock, $0.01 Par Value |
| 2023-12-31 | Tross Stuart A | Buy | 1 006 | Common Stock, $0.01 Par Value |
| 2023-06-30 | Tross Stuart A | Buy | 4 012 | Common Stock, $0.01 Par Value |
| 2024-02-04 | Blank Burkhard | Buy | 152 905 | Common Stock, $0.01 Par Value |
| INSIDER POWER |
|---|
| 30.59 |
| Last 96 transactions |
| Buy: 5 265 399 | Sell: 2 722 728 |
Forecast:
16:00 - $4.09
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.09
Forecast 2: 16:00 - $4.09
Forecast 3: 16:00 - $4.09
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.08 (-0.49% ) |
| Volume | 1.290 mill |
| Avg. Vol. | 2.98 mill |
| % of Avg. Vol | 43.25 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MNKD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $3.44 | N/A | Active |
|---|
MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-03 06:00:00 - Press Release
Mannkind Repays Certain Debt Obligations
Danbury, conn. and westlake village, calif., april 03, 2024 (globe newswire) -- mannkind corporation (nasdaq: mnkd), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has repaid in full all outstanding indebtedness under both its credit and security agreement with midcap financial trust (the “loan agreement”) and its convertible promissory note issued to mann group llc (the “note”).
2024-03-26 16:05:00 - Press Release
Mannkind Announces Cfo Transition
Steven b. binder announces planned retirement and is appointed executive vice president, special projects, effective april 22, 2024, through december 31, 2024 christopher prentiss appointed chief financial officer, effective april 22, 2024 danbury, conn. and westlake village, calif.
2024-03-11 06:05:00 - Press Release
Inhale-3 Study's Initial Meal Challenge Results Comparing Afrezza® Head-to-head With Multiple Daily Injections (mdi) And Insulin Pumps
Post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered through mdi or insulin pumps subjects utilizing inhaled insulin experienced a 22% decrease in mean glucose excursions in the first two hours compared to the standard of care 17-week primary endpoint results will be presented during a 90-minute symposium at the american diabetes association's scientific sessions in june danbury, conn. and westlake village, calif.
2024-03-05 06:05:00 - Press Release
Mannkind Announces New Clinical Data From Inhale-3 Study To Be Presented By Dr. Irl B. Hirsch At Attd On March 8
Dr. hirsch to present meal challenge results when switching from multiple daily injections (mdi) or insulin pumps to inhaled insulin (afrezza® (insulin human) inhalation powder) dr. hirsch to present meal challenge results when switching from multiple daily injections (mdi) or insulin pumps to inhaled insulin (afrezza® (insulin human) inhalation powder)
2024-03-04 13:01:00 - Press Release
Mannkind Corporation Announces Participation At Upcoming Conferences
Westlake village, calif. and danbury, conn., march 04, 2024 (globe newswire) -- mannkind corporation (nasdaq: mnkd), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming conferences.
Latest News
2024-03-04 13:01:00 - GlobeNewsWire
MannKind Corporation Announces Participation at Upcoming Conferences
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming conferences.
2024-02-27 22:33:06 - Seeking Alpha
MannKind Corporation (MNKD) Q4 2023 Earnings Call Transcript
2024-02-27 19:01:16 - Zacks Investment Research
Here's What Key Metrics Tell Us About MannKind (MNKD) Q4 Earnings
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
2024-02-27 18:36:09 - Zacks Investment Research
MannKind (MNKD) Q4 Earnings and Revenues Surpass Estimates
MannKind (MNKD) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.07 per share a year ago.
2024-02-20 06:00:00 - GlobeNewsWire
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 fourth quarter and full year financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, February 27, 2024.
2024-02-14 19:49:34 - Seeking Alpha
MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
MannKind sold a 10% stake in Tyvaso DPI for $150 million upfront, with an additional $50 million possible, indicating the potential value of the remaining 9% to be upwards of $1.8 billion. Liquidia's likely entry into the market with a competing formulation poses a slight concern but is unlikely to significantly impact MannKind's market share. MannKind's Q3 earnings showed a strong year-over-year surge, but concerns over equity dilution and a debt-heavy balance sheet remain.
2024-02-12 22:49:38 - Seeking Alpha
Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices
Liquidia's stock has increased in value by 209.32% since June 2022. Liquidia's PAH drug, Yutrepia, is expected to launch in the first or second quarter of 2024, potentially leading to profitability. Liquidia has gained a major partnership for a sustained-release inhaled Treprostinil product, which could compete with United Therapeutics' revenue products.
2024-01-25 17:29:17 - InvestorPlace
3 Biotech Stocks to Sell in January Before They Crash and Burn
The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as companies' performance relies heavily on drug approvals.
2024-01-02 06:19:00 - Market Watch
MannKind in royalty agreement with Sagard Healthcare for Tyvaso DPI
MannKind Corp. MNKD, -1.62% said Tuesday it has entered a royalty agreement with Sagard Healthcare under which the latter will receive 1% of royalty sales of Tyvaso DPI inhalation powder for up to $200 million. United Therapeutics Corp. licensed Tyvaso DPI from MannKind in 2018 and started to market it in June 2022 as a treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease following U.S. FDA approval.
2023-12-28 06:00:00 - GlobeNewsWire
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 11:15 AM PST at the Westin St. Francis Hotel in San Francisco, California.